Bezuclastinib

Bezuclastinib is an investigational new drug that is being evaluated for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. It acts as an inhibitor of tyrosine-protein kinase KIT.[1][2] [3][4]

## References

1. ↑ "Bezuclastinib - Cogent Biosciences". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800042241.
2. ↑ "Systemic Mastocytosis: State of the Art". Current Hematologic Malignancy Reports 19 (5): 197–207. August 2024. doi:10.1007/s11899-024-00737-8. PMID 39187708.
3. ↑ "Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial". JAMA Oncology 7 (9): 1343–1350. September 2021. doi:10.1001/jamaoncol.2021.2086. PMID 34236401.
4. ↑ "Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)". 2026-04-01. https://www.drugs.com/nda/bezuclastinib_260401.html.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Bezuclastinib. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Bezuclastinib&oldid=4433713"